VERONA PHARMA P/S (VRNA) Lowered to “Hold” at ValuEngine
ValuEngine cut shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a buy rating to a hold rating in a research note released on Wednesday morning.
A number of other equities research analysts have also recently issued reports on VRNA. Zacks Investment Research cut shares of VERONA PHARMA P/S from a buy rating to a hold rating in a report on Friday, November 9th. Wedbush set a $56.00 target price on shares of VERONA PHARMA P/S and gave the company a buy rating in a research note on Tuesday, August 7th. Finally, Jefferies Financial Group reiterated a buy rating and issued a $26.00 target price on shares of VERONA PHARMA P/S in a research note on Friday, August 10th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $31.33.
VRNA stock opened at $11.67 on Wednesday. VERONA PHARMA P/S has a 52-week low of $10.19 and a 52-week high of $25.55. The stock has a market cap of $153.16 million, a price-to-earnings ratio of -4.84 and a beta of -1.37.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Foresite Capital Management IV LLC bought a new stake in VERONA PHARMA P/S (NASDAQ:VRNA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,302 shares of the company’s stock, valued at approximately $104,000. VERONA PHARMA P/S accounts for approximately 0.0% of Foresite Capital Management IV LLC’s holdings, making the stock its 21st largest position. Foresite Capital Management IV LLC owned about 0.06% of VERONA PHARMA P/S at the end of the most recent reporting period. Institutional investors own 56.23% of the company’s stock.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Story: How do candlesticks reflect price movement?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.